PMID- 30343686
OWN - NLM
STAT- MEDLINE
DCOM- 20190930
LR  - 20190930
IS  - 1872-6240 (Electronic)
IS  - 0006-8993 (Linking)
VI  - 1699
DP  - 2018 Nov 15
TI  - Soluble epoxide hydrolase inhibition alleviated cognitive impairments via 
      NRG1/ErbB4 signaling after chronic cerebral hypoperfusion induced by bilateral 
      carotid artery stenosis in mice.
PG  - 89-99
LID - S0006-8993(18)30370-6 [pii]
LID - 10.1016/j.brainres.2018.07.002 [doi]
AB  - Cerebral ischemic stroke is associated with a high rate of incidence, prevalence 
      and mortality globally. Carotid artery stenosis, which is mainly caused by 
      atherosclerosis plaque, results in chronic cerebral hypoperfusion and 
      predominantly increases the risk of ischemic stroke. In the present study, we 
      used bilateral common carotid artery stenosis (BCAS) model by placing microcoils 
      of 0.18 mm diameter encompassing both common carotid arteries respectively, to 
      mimic the pathogenesis of carotid artery atherosclerosis and intensively explore 
      the pathology. We found that BCAS injury for 1 month impaired spatial cognitive 
      functions significantly, and inhibited synaptic plasticity, including hippocampal 
      long-term potentiation (LTP) inhibition, dendritic spine density reduction and 
      synaptic associative proteins disorder. BCAS-induced cerebral hypoperfused mice 
      treated with 1-(1-propanoylpiperidin-4-yl)-3-[4-(trifluoromethoxy)phenyl]urea 
      (TPPU), a potent soluble epoxide hydrolase (sEH) inhibitor, exhibited 
      amelioration of cognitive dysfunction and improved synaptic plasticity. The 
      neural protective effects of TPPU on BCAS-induced cerebral hypoperfusion might 
      due to activation of neuregulin-1 (NRG1)/ErbB4 signaling, and triggered PI3K-Akt 
      pathways subsequently. Our results suggested that sEH inhibition could exert 
      multi-target protective effects and alleviate spatial cognitive dysfunctions 
      after chronic cerebral hypoperfusion in mice.
CI  - Copyright (c) 2018 Elsevier B.V. All rights reserved.
FAU - Hao, Jiahuan
AU  - Hao J
AD  - Department of Traumatology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430030, PR China; Department of 
      Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of 
      Science and Technology, Wuhan 430030, PR China.
FAU - Chen, Yuxue
AU  - Chen Y
AD  - Department of Immunology and Rheumatology, Tongji Hospital, Tongji Medical 
      College, Huazhong University of Science and Technology, Wuhan 430000, PR China.
FAU - Yao, Ensheng
AU  - Yao E
AD  - Department of Neurology, First Affiliated Hospital, School of Medicine, Shihezi 
      University, Xinjiang, PR China.
FAU - Liu, Xinghua
AU  - Liu X
AD  - Department of Traumatology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430030, PR China; Department of 
      Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of 
      Science and Technology, Wuhan 430030, PR China. Electronic address: 
      liu_xingh@126.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180703
PL  - Netherlands
TA  - Brain Res
JT  - Brain research
JID - 0045503
RN  - 0 (1-trifluoromethoxyphenyl-3-(1-propionylpiperidine-4-yl)urea)
RN  - 0 (Neuregulin-1)
RN  - 0 (Nootropic Agents)
RN  - 0 (Nrg1 protein, mouse)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Piperidines)
RN  - EC 2.7.10.1 (Erbb4 protein, mouse)
RN  - EC 2.7.10.1 (Receptor, ErbB-4)
RN  - EC 3.3.2.- (Epoxide Hydrolases)
SB  - IM
MH  - Animals
MH  - Brain/drug effects/metabolism/pathology
MH  - Carotid Stenosis/*drug therapy/metabolism/pathology/psychology
MH  - Cognitive Dysfunction/*drug therapy/etiology/metabolism/pathology
MH  - Disease Models, Animal
MH  - Epoxide Hydrolases/*antagonists & inhibitors
MH  - Male
MH  - Mice, Inbred C57BL
MH  - Neuregulin-1/metabolism
MH  - Nootropic Agents/*pharmacology
MH  - Phenylurea Compounds/*pharmacology
MH  - Piperidines/*pharmacology
MH  - Random Allocation
MH  - Receptor, ErbB-4/metabolism
MH  - Signal Transduction/drug effects
MH  - Tissue Culture Techniques
OTO - NOTNLM
OT  - BCAS
OT  - Cognitive function
OT  - Neuregulin-1
OT  - Soluble epoxide hydrolase inhibitor
OT  - Synaptic plasticity
EDAT- 2018/10/23 06:00
MHDA- 2019/10/01 06:00
CRDT- 2018/10/23 06:00
PHST- 2018/02/28 00:00 [received]
PHST- 2018/07/01 00:00 [revised]
PHST- 2018/07/02 00:00 [accepted]
PHST- 2018/10/23 06:00 [entrez]
PHST- 2018/10/23 06:00 [pubmed]
PHST- 2019/10/01 06:00 [medline]
AID - S0006-8993(18)30370-6 [pii]
AID - 10.1016/j.brainres.2018.07.002 [doi]
PST - ppublish
SO  - Brain Res. 2018 Nov 15;1699:89-99. doi: 10.1016/j.brainres.2018.07.002. Epub 2018 
      Jul 3.